Biotec Pharmacon ASA

MedTech

Insempra, | July 26, 2022

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating ...

Tevogen Bio | August 11, 2020

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Medical

Novavax, Inc. | January 31, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Medical

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...